Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
11 July 2023 - 1:48AM
Guerbet: Guerbet strengthens its Executive Committee with two new
appointments to accelerate its commercial and industrial
development
Guerbet strengthens its Executive
Committee with two new appointments to accelerate its commercial
and industrial development
- Dan Raffi appointed Director of Commercial Operations
- Raoul Bernhardt appointed Director of Industrial
Operations
Villepinte, 10 July
2023: Guerbet (FR0000032526 GBT), a
global specialist in contrast agents and solutions for medical
imaging, announces the strengthening of its management team with
two appointments. Dan Raffi and Raoul Bernhardt have joined the
Group as Director of Commercial Operations and Director of
Industrial Operations respectively. They will both become members
of Guerbet’s Executive Committee
Dan RAFFI - Director of Commercial
Operations
Raoul Bernhardt - Director of Industrial
Operations
Guerbet’s Executive Committee now has 9
members:
- David Hale, Chief Executive Officer
- Charlotte Bamière, Director of Legal Affairs
- Raoul Bernhardt, Director of Industrial Operations
- Philippe Bourrinet, Director of Development, Medical &
Regulatory Affairs, and Group Chief Pharmacist
- Valérie Brissart, Director of Diagnostic Imaging
- Jérôme Estampes, Chief Financial Officer and Senior VP Business
Development and Licensing
- Leïla Mechaï, Director of Human Resources and Corporate Social
Responsibility
- François Nicolas, Director of R&D, R&I and Chief
Digital Officer
- Dan Raffi, Director of Commercial Operations
Upcoming events:
Publication of first-half annual
revenue20 July 2023 after trading
About Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. That is our purpose. We are a
world leader in medical imaging, offering a complete range of
pharmaceutical products, medical devices, and digital and AI
solutions for diagnostic and interventional imaging. Pioneers in
contrast media for 95 years, with more than 2,830 employees
worldwide, we are constantly innovating and devote 8% to 10% of our
revenue to research and development in five centres in France,
Israel, and the United States. Guerbet (GBT) is listed on Euronext
Paris (segment B – mid caps) and generated €753 million in revenue
in 2022. For more information, please visit www.guerbet.com.
- 2023 07 10 - GUERBET - Appointments in Executive Committee
Guerbet (LSE:0ELV)
Historical Stock Chart
From Apr 2024 to May 2024
Guerbet (LSE:0ELV)
Historical Stock Chart
From May 2023 to May 2024
